BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24:3354-3360. [PMID: 16849749 DOI: 10.1200/jco.2005.05.1573] [Cited by in Crossref: 134] [Cited by in F6Publishing: 46] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Bower M, Metzger T, Robbins K, Tomalty D, Válek V, Boudný J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB s. 2010;12:31-36. [PMID: 20495642 DOI: 10.1111/j.1477-2574.2009.00117.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
2 Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. [PMID: 26311588 DOI: 10.1186/s12885-015-1606-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Petrelli F, Barni S. Bevacizumab in advanced breast cancer: an opportunity as second-line therapy? Med Oncol 2012;29:1-4. [PMID: 21161443 DOI: 10.1007/s12032-010-9773-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 2007;55:457-8. [PMID: 17951904 DOI: 10.4103/0301-4738.36482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
5 Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther 2013;6:1393-8. [PMID: 24124381 DOI: 10.2147/OTT.S51164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R, Tatum C. Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI): Multi-Institutional Registry. J Oncol 2009;2009:539795. [PMID: 19888427 DOI: 10.1155/2009/539795] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
7 Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, Zhao Q, Nie Y, Cai X, Li Q, Fang W, Li H, Wang N, Chen Y, Peng C, Fang H, Shen L. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer 2020;20:131. [PMID: 32070312 DOI: 10.1186/s12885-020-6557-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Choi YI, Lee SH, Ahn BK, Baek SU, Park SJ, Kim YS, Shin SH. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008;40:33-5. [PMID: 19688063 DOI: 10.4143/crt.2008.40.1.33] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
9 Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007;9:320-8. [PMID: 17686384 DOI: 10.1007/s11906-007-0058-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
10 Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624-630. [PMID: 18539884 DOI: 10.1215/15228517-2008-010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
11 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: report of two cases. World J Gastroenterol 2011;17:4440-4. [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
12 Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. Onco Targets Ther 2015;8:2407-13. [PMID: 26366095 DOI: 10.2147/OTT.S88679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
13 McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DM. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol 2012;127:362-6. [PMID: 22885866 DOI: 10.1016/j.ygyno.2012.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol. 2015;7:47-54. [PMID: 26090075 DOI: 10.4251/wjgo.v7.i6.47] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008;98:1312-9. [PMID: 18362940 DOI: 10.1038/sj.bjc.6604311] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
17 Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol. 2012;18:25-33. [PMID: 22228967 DOI: 10.3748/wjg.v18.i1.25] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
18 Stutz M, Mamo A, Valenti D, Hausvater A, Cabrera T, Metrakos P, Chaudhury P, Steacy G, Garoufalis E, Kavan P. Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer. Gastroenterol Res Pract 2015;2015:715102. [PMID: 25815009 DOI: 10.1155/2015/715102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013;4:299-307. [PMID: 23997941 DOI: 10.3978/j.issn.2078-6891.2013.030] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
21 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 George TJ, Ivey AM, Ali A, Lee JH, Wang Y, Daily KC, Ramnaraign BH, Tan SA, Terracina KP, Read TE, Dang LH, Iqbal A. Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. Oncologist 2021;26:362-e724. [PMID: 33512054 DOI: 10.1002/onco.13689] [Reference Citation Analysis]
23 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
24 Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26:32-37. [PMID: 18498064 DOI: 10.1007/s12032-008-9077-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
25 Bang YH, Kim JE, Lee JS, Kim SY, Kim KP, Kim TW, Hong YS. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Sci Rep 2021;11:7118. [PMID: 33782470 DOI: 10.1038/s41598-021-86482-x] [Reference Citation Analysis]
26 Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012;15:275-86. [PMID: 22382585 DOI: 10.1007/s10456-012-9260-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
27 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
28 Yang M, Reynoso J, Bouvet M, Hoffman RM. A transgenic red fluorescent protein-expressing nude mouse for color-coded imaging of the tumor microenvironment. J Cell Biochem 2009;106:279-84. [PMID: 19097136 DOI: 10.1002/jcb.21999] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
29 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
30 Akeel N, Toonsi WA. Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer. Cureus 2021;13:e12831. [PMID: 33628692 DOI: 10.7759/cureus.12831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ranieri G, Niccoli Asabella A, Altini C, Fazio V, Caporusso L, Marech I, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Rubini G, Gadaleta CD. A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther 2016;9:7527-35. [PMID: 28003766 DOI: 10.2147/OTT.S112670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
32 Chang YJ, Chen LJ, Chang YJ, Chung KP, Lai MS. Risk groups defined by Recursive Partitioning Analysis of patients with colorectal adenocarcinoma treated with colorectal resection. BMC Med Res Methodol. 2012;12:2. [PMID: 22214198 DOI: 10.1186/1471-2288-12-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
33 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:53-58. [PMID: 23378775 DOI: 10.2147/ott.s41383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
35 Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K, Hamaguchi T, Shimada Y. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 2012;30:1690-6. [PMID: 21894500 DOI: 10.1007/s10637-011-9743-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
36 Bhutiani N, Akinwande O, Martin RC. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases. World J Surg. 2016;40:1178-1190. [PMID: 26711640 DOI: 10.1007/s00268-015-3386-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
37 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011;26:823-833. [PMID: 21286919 DOI: 10.1007/s00384-011-1149-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
38 Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol. 2012;18:1104-1109. [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
39 Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010;3:69-82. [PMID: 20616958 DOI: 10.2147/ott.s5256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 21] [Article Influence: 0.1] [Reference Citation Analysis]
40 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
41 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
42 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Fairchild AH, White SB. Decision Making in Interventional Oncology: Intra-arterial Therapies for Metastatic Colorectal Cancer-Y90 and Chemoembolization. Semin Intervent Radiol 2017;34:87-91. [PMID: 28579675 DOI: 10.1055/s-0037-1601854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007;13:5867-76. [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
45 Hoffman RM. Imaging In Mice With Fluorescent Proteins: From Macro To Subcellular. Sensors (Basel) 2008;8:1157-73. [PMID: 27879758 DOI: 10.3390/s8021157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
46 Mahmood U, Upadhyay R. Current and Future Imaging Paradigms in Colorectal Cancer. Semin Colon Rectal Surg 2007;18:132-8. [PMID: 18516215 DOI: 10.1053/j.scrs.2007.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]